AR115506A1 - MULTI-SPECIFIC BINDING PROTEINS FOR THE TREATMENT OF CANCER - Google Patents

MULTI-SPECIFIC BINDING PROTEINS FOR THE TREATMENT OF CANCER

Info

Publication number
AR115506A1
AR115506A1 ARP190101568A ARP190101568A AR115506A1 AR 115506 A1 AR115506 A1 AR 115506A1 AR P190101568 A ARP190101568 A AR P190101568A AR P190101568 A ARP190101568 A AR P190101568A AR 115506 A1 AR115506 A1 AR 115506A1
Authority
AR
Argentina
Prior art keywords
proteins
cancer
treatment
binding proteins
specific binding
Prior art date
Application number
ARP190101568A
Other languages
Spanish (es)
Inventor
Vladimir H Voynov
Justin Scheer
Pankaj Gupta
Priyanka Gupta
Philip Nicholas Gorman
Rajkumar Ganesan
Michael Dziegelewski
Paul Adam
Susanne Hipp
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR115506A1 publication Critical patent/AR115506A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Proteínas de fijación a DLL3 / CD3. También ácidos nucleicos que codifican estas proteínas; métodos para preparar estas proteínas; células huésped que expresan o pueden expresar estas proteínas; composiciones que comprenden estas proteínas; y usos de estas proteínas o estas composiciones, en particular, con fines terapéuticos en el campo de las enfermedades cancerosas.DLL3 / CD3 binding proteins. Also nucleic acids that encode these proteins; methods for preparing these proteins; host cells that express or can express these proteins; compositions comprising these proteins; and uses of these proteins or these compositions, in particular, for therapeutic purposes in the field of cancer diseases.

ARP190101568A 2018-06-09 2019-06-07 MULTI-SPECIFIC BINDING PROTEINS FOR THE TREATMENT OF CANCER AR115506A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18176888 2018-06-09

Publications (1)

Publication Number Publication Date
AR115506A1 true AR115506A1 (en) 2021-01-27

Family

ID=62712762

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101568A AR115506A1 (en) 2018-06-09 2019-06-07 MULTI-SPECIFIC BINDING PROTEINS FOR THE TREATMENT OF CANCER

Country Status (1)

Country Link
AR (1) AR115506A1 (en)

Similar Documents

Publication Publication Date Title
AR108516A1 (en) ANTI-PD1 AND ANTI-LAG3 ANTIBODY MOLECULES FOR CANCER TREATMENT
AR115389A1 (en) CD73 ANTAGONIST ANTIBODY
JOP20200313A1 (en) Dll3-cd3 bispecific antibodies
AR120138A1 (en) MULTISPECIFIC BINDING PROTEINS FOR TREATMENT AGAINST CANCER
MX2017014908A (en) Trispecific binding proteins and methods of use.
MX2019006045A (en) Psma targeting trispecific proteins and methods of use.
SV2018005634A (en) ANTI-BCMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN BCMA AND CD3, AND USES OF THESE
MX2020001996A (en) Anti-cd137 molecules and use thereof.
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2020009514A (en) Anti-claudin 18.2 antibodies.
BR112017024384A2 (en) bacteria modified to reduce hyperphenylalaninemia
MX2019009468A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
BR112019011450A2 (en) modified natural killer cells and their use
UY36687A (en) ANTIBODIES AGAINST OX40 AND ITS USES
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
EA201700181A1 (en) COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
BR112019004711A2 (en) chimeric antigen receptors comprising bcma specific type III fibronectin domains and uses thereof
UY37279A (en) TGF-BETA ANTIBODIES AND JOINT FRAGMENTS OF THE SAME
PE20210110A1 (en) MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF USE
JOP20210085A1 (en) Anti-TNF?-antibodies and functional fragments thereof
UY37630A (en) PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT
MX2020001287A (en) Braf-specific tcrs and uses thereof.
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.
AR115506A1 (en) MULTI-SPECIFIC BINDING PROTEINS FOR THE TREATMENT OF CANCER